VolitionRx Limited announced a 112% revenue increase in the first half of 2026, reaching $1.4 million, driven by progress in sepsis detection, cancer diagnostics, and veterinary tests. The company is preparing a lung cancer reimbursement submission in Europe and has submitted a manuscript for a feline lymphoma test expected to trigger a $5 million milestone payment. VolitionRx is also advancing collaborations with major global diagnostic firms and developing a breakthrough finger-prick test for sepsis, aiming to expand market reach. These developments position the company for significant growth in multi-billion-dollar markets for human and animal health diagnostics.
Mustafa Suleyman, co-founder of Microsoft’s DeepMind AI unit, criticized Anthropic’s method of training its AI chatbots, like Claude, to "push back" on commands and believe they might be conscious. Suleyman argues this approach is reckless and could ...
Gasoline prices jumped significantly, with WTI crude nearing $100 a barrel. Interactive Brokers senior economist Jose Torres suggests that oil prices above $120 a barrel pose a serious risk to consumer spending and could trigger a recession, especial...
Traders have invested $7 billion into the iShares 20+ Year Treasury Bond ETF (TLT) ahead of a Federal Reserve rate hike decision, hoping for a "jackpot mode" scenario where long-term yields drop significantly. This influx comes despite TLT's 35% loss...
Imbal hasil Treasury 10 tahun AS mencapai level tertinggi sejak 2007, memicu kekhawatiran akan kerentanan di sektor perumahan, properti komersial, dan perusahaan dengan utang besar. Para ahli memperingatkan bahwa dampak terburuk akan terasa dalam 12-...
HIVE Digital Technologies, through its subsidiary BUZZ HPC, has formed a strategic partnership with ProCogia, an applied-AI and data engineering company. This collaboration will see ProCogia utilizing BUZZ HPC's Canadian data centers to provide AI so...
